Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8353 + Pembrolizumab in Advanced Malignancies
NCT02972034Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of mk-8353 in malignant neoplasms (advanced stage) and colorectal cancer (CRC) (4 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced an Adverse Event (AE) up to 27 months, Number of Participants Who Discontinued Study Drug Due to an Adverse Event (AE) up to 24 months and 1 more. Started Jan 2017; status: terminated.
02
Drugs
mk-8353
03
Conditions
malignant neoplasms (advanced stage)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02972034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02972034.